Therapeutic applications of transcription factor decoy oligonucleotides

Journal of Clinical Investigation

Volumn 106, Issue 9, 2000, Pages 1071-1075

  Mann, Michael J ^a   Dzau, Victor J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLIGONUCLEOTIDE; TRANSCRIPTION FACTOR;

ANGIOGENESIS; APOPTOSIS; ARTERY INJURY; BINDING SITE; CARDIOMYOPATHY; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; GENE THERAPY; GENETIC MANIPULATION; GENETIC TRANSFECTION; GRAFT FAILURE; GRAFT REJECTION; HEART FAILURE; HUMAN; NEOPLASM; PRIORITY JOURNAL; PROTEIN DNA BINDING; RESTENOSIS; REVIEW; STRESS; VIRUS INFECTION;

EID: 0033767577     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI11459     Document Type: Review

References (42)

1. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides
2. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo
3. Unusual proliferation arrest and transcriptional control properties of a newly discovered E2F family member E2F-6
4. In vivo identification of a negative regulatory element in the mouse renin gene using direct gene transfer
5. Transcription factor decoy to study the molecular mechanism of negative regulation of renin gene expression in the liver in vivo
6. Stranger in a strange land: The pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries
7. Kinetics of vein graft hyperplasia: Association with tangential stress
8. Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury
9. Vein graft gene therapy using E2F decoy oligonucleotides: Target gene inhibition in human veins and long term resistance to atherosclerosis in rabbits
10. Cell cycle inhibition preserves endothelial function in genetically engineered vein grafts
11. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial
12. Impact of a color-flow duplex surveillance program on infrainguinal vein graft patency: A five year experience
13. NF-κB as a primary regulator of the stress response
14. Transcriptional regulation of endothelial cell adhesion molecules: NF-κB and cytokine-inducible enhancers
15. Use of phosphorothioate-modified oligodeoxynucleotides to inhibit NF-κB expression and lymphocyte function
16. Anti-inflammatory gene therapy directed at the airway epithelium
17. Suppressed severity, of collagen-induced arthritis by in vivo transfection of nuclear factor κB decoy oligodeoxynucleotides as a gene therapy
18. Intratumoral injection of oligonucleotides to the NF κB binding site inhibits cachexia in a mouse tumor model
19. Transcription factor decoy for nuclear factor-κB inhibits tumor necrosis factor-alpha-induced expression of interleukin-6 and intracellular adhesion molecule-1 in endothelial cells
20. A novel strategy for myocardial protection using in vivo transfection of cis element 'decoy' against NFκB binding site: Evidence for a role of NFκB in ischemia-reperfusion injury
21. In vivo transfection of cis element 'decoy' against nuclear factor-κB binding site prevents myocardial infarction
22. Activation of nuclear factor-κB in C6 rat glioma cells after transfection with glia maturation factor
23. AP-2beta represses D(1A) dopamine receptor gene transcription in neuro2a cells
24. NO-Evoked macrophage apoptosis is attenuated by cAMP-induced gene expression
25. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta 12, 14-prostaglandin J2
26. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway
27. Etoposide and cisplatin induced apoptosis in activated RAW 264.7 macrophages is attenuated by cAMP-induced gene expression
28. Targeted disruption of stat6 DNA binding activity by an oligonucleotide decoy blocks IL-4-driven T(H)2 cell response
29. Dual blockade of cyclic AMP response element-(CRE) and AP-1-directed transcription by CRE-transcription factor decoy oligonucleotide. Gene-specific inhibition of tumor growth
30. CRE-Transcription factor decoy oligonucleotide inhibition of MCF-7 breast cancer cells: Cross-talk with p53 signaling pathway
31. Attenuation of interleukin-8 production by inhibiting nuclear factor-κB translocation using decoy oligonucleotides
32. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia
33. Fusigenic viral liposome for gene therapy in cardiovascular diseases
34. Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues
35. Antisense oligodeoxynucleotides prevent acute cardiac allograft rejection via a novel, nontoxic, highly efficient transfection method
36. A pressure-mediated nonviral method for efficient arterial gene and oligonucleotide transfer
37. Gene regulation by decoy approach (I): Synthesis and properties of photocrosslinked oligonucleotides
38. A non-nucleotide-bridged DNA decoy inhibits renal epithelial nitric oxide synthase expression
39. Developing aptamers into therapeutics
40. Escort aptamers: A delivery service for diagnosis and therapy
41. Selection and characterization of an RNA decoy for transcription factor NF-κB
42. Sequence-specific inhibition of a transcription factor by circular dumbbell DNA oligonucleotides